ABEO Stock Analysis: Buy, Sell, or Hold?
ABEO - Abeona Therapeutics Inc. Common Stock
$5.72
-0.03 (-0.52%)
▼
5d:
+0.88%
30d:
+3.62%
90d:
+29.41%
BUY
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 13, 2026
Get Alerted When ABEO Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: ABEO shows positive signals but monitor for confirmation. Market pricing in 1.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: ABEO shows positive signals but monitor for confirmation. Market pricing in 1.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$8.48
Based on 7.0% avg growth
INTRINSIC VALUE TODAY
$5.26
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 21.1x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ABEO is currently trading at $5.72, which is considered extended relative to its 30-day fair value range of $5.39 to $5.74. The stock's valuation (Forward PE: 19.9) is in line with its historical norms (21.1). Remarkably, the market is currently pricing in an annual earnings decline of 1.8% over the next few years. This aligns with recent fundamental challenges.
Technical Outlook: Technically, ABEO is in a uptrend. The price is approaching resistance at $5.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ABEO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.71 (+244.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, ABEO is in a uptrend. The price is approaching resistance at $5.88. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ABEO has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $19.71 (+244.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$5.39 -
$5.74
Company Quality Score
63/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
61.9%
All Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 244.7% below Wall St target ($19.71)
Trading Range Analysis
30-Day Trading Range
$5.39 -
$5.74
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$5.24
Resistance Level
$5.88
Current Trend
Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
19.95
Wall Street Target
$19.71
(+244.7%)
Revenue Growth (YoY)
-100.0%
Profit Margin
454.9%
Valuation Discount vs History
-1.8% cheaper
PE vs Historical
20.0 vs 21.1
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-1.8%
(market-implied from PE analysis)
1-Year Target
$5.62
(-2%)
2-Year Target
$5.52
(-4%)
3-Year Target
$5.42
(-5%)
3-Yr Target (if PE normalizes)
(PE: 20→21)
$5.73
(+0%)
📈
Valuation based on Current Earnings
Trailing PE: 6.16 | Current EPS (TTM): $0.95
Bull Case
$3.22
(-44%)
Analyst growth -50.0%, PE expands to 6.8
Base Case
$2.93
(-49%)
Market implied -50.0%, PE stable at 6.2
Bear Case
$3.98
(-30%)
Severe decline -20.0%, PE contracts to 5.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 20.0 to 21.1
Stabilization Target:
$6.05
(+5.8%)
PE Expansion Potential:
+5.8%
Share & Embed Analysis
Last updated: June 24, 2026 5:35 AM ET
Data refreshes hourly during market hours. Next update: 6:35 AM
Data refreshes hourly during market hours. Next update: 6:35 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ABEO showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Eric Crombez
SELL
16284 shares
2026-02-02
Leila Alland
SELL
18065 shares
2026-02-02
Mark Alvino
SELL
2000 shares
2026-02-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 54 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$31 | 62 BUY |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$122 | 55 HOLD |
|
DYN
Dyne Therapeutics Inc |
STRONG BUY
14 analysts |
$38 | 62 BUY |
|
DNTH
Dianthus Therapeutics In… |
STRONG BUY
12 analysts |
$128 | 57 HOLD |
